Kris Hage

Ms. Kris Hage

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2024 in Sexually Transmitted Infections
Verified
Journal Article
Closed access
PDF file
KHKris Hage
Kris Hage
ABAnders Boyd
Anders Boyd
ECEline L M Op de Coul
Eline L M Op de Coul
DSDanja Sarink
Danja Sarink
EHElske Hoornenborg
Elske Hoornenborg
MPMaria Prins
Maria Prins
Objectives Studies showed that men who have sex with men (MSM), including those using pre-exposure prophylaxis (PrEP), are at increased risk of hepatitis C virus (HCV) infection. We evaluated HCV prevalence and incidence, along with their associated determinants, in a cohort of PrEP-using individuals in the Netherlands. Methods In 2019, the Netherlands launched a 5-year national programme that offers subsidised PrEP to eligible individuals. We used prospectively collected data from individuals registered in this programme between 2019 and 2022. Individuals underwent annual testing for HCV antibodies and additional HCV-RNA testing when antibodies were present. We calculated the prevalence of past/current HCV infection at first visit and overall incidence rate (IR) during follow-up. Univariable logistic and Poisson regression models were used to identify determinants associated with past/current prevalent or incident HCV infection, respectively. Behavioural factors referred to those occurring in the previous 6 months. Results A total of 10 563 (n=10 319, 97.7% MSM) were included. At first visit, 66 of 10 563 (0.6%) had a past/current HCV infection, which was associated with older age [odds ratio (OR) per 10 years=1.57, 95% confidence interval (CI)=1.31 to 1.88], the use of PrEP before first visit (OR=3.03, 95% CI=1.79 to 5.13), receptive condomless anal sex (CAS) (OR=2.73, 95% CI=1.25 to 5.98), chemsex (OR=2.44, 95% CI=1.49 to 3.99) and injecting drug use (IDU) (OR=6.61, 95% CI=2.35 to 18.61). Among 9851 individuals contributing to 17 150 person-years (PYs) of follow-up, 64 incident HCV infections (IR=0.37 per 100 PYs, 95% CI=0.29 to 0.48) were identified. Factors associated with incident HCV infection were receptive CAS [incidence rate ratio (IRR)=2.59, 95% CI=1.12 to 6.02], chemsex (IRR=1.78, 95% CI=1.06 to 2.98), sexually transmitted infection diagnosis (IRR=2.30, 95% CI=1.23 to 4.31) and IDU (IRR=6.15, 95% CI=2.20 to 17.18). Conclusions Past/current prevalence and incidence of HCV were low among individuals in the Dutch PrEP programme. Infections were associated with behaviour known to be associated with HCV. Instead of annual HCV testing, as stated in most PrEP care guidelines, testing frequency for HCV could be based on behaviours associated with HCV acquisition.

23 June 2025 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Open access
KHKris Hage
Kris Hage
JKJeffrey Koole
Jeffrey Koole
ABAnders Boyd
Anders Boyd
AMAmy Matser
Amy Matser
UDUdi Davidovich
Udi Davidovich
MPMaria Prins
Maria Prins
Objective: To assess the hepatitis C virus (HCV) prevalence, incidence, and associated determinants among men who have sex with men (MSM) without HIV in Amsterdam, the Netherlands. Methods: We used data from the Amsterdam Cohort Studies (2012–2021) to calculate the prevalence of past/current HCV infection at the first study visit and incidence rate of primary HCV infection during follow-up. We identified determinants associated with incident HCV infection using univariable Bayesian exponential survival models. Phylogenetic analysis was conducted to compare HCV sequences of MSM without HIV to those from MSM with HIV and those using HIV pre-exposure prophylaxis. Results: A total of 926 MSM were included. At first visit, 2/926 (0.2%) had a past/current HCV infection. Among 891 participants contributing to 6083.30 person-years of follow-up, three incident HCV infections were observed (incidence rate = 0.05/100 person-years). These infections were observed between 2014 and 2018, and all participants had never used HIV pre-exposure prophylaxis. Incident infections were associated with receptive condomless anal sex, having 1–10 sexual partners vs. none, recent injecting drug use (IDU), ever IDU, and fisting, albeit there was substantial uncertainty for all determinants (i.e. 95% credible intervals included one). Phylogenetic analysis revealed that one HCV-RNA sequence was closely related to HCV sequences from MSM with HIV. Conclusion: While HCV infection is uncommon among MSM without HIV, the risk of infection seems to increase among those with specific behaviors. HCV screening for MSM without HIV should be focused on those reporting these behaviors.

16 October 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
KHKris Hage
Kris Hage
MKMarita van de Kerkhof
Marita van de Kerkhof
ABAnders Boyd
Anders Boyd
JCJoanne M. Carson
Joanne M. Carson
ANAstrid M. Newsum
Astrid M. Newsum
MPMaria Prins
Maria Prins
We assessed the predictive capacity of the HCV-MOSAIC risk score, originally developed for primary early HCV infection, as a screening tool for HCV reinfection in 103 men who have sex with men (MSM) with HIV using data from the MOSAIC cohort, including MSM with HIV/HCV-coinfection who became reinfected (cases, n = 27) or not (controls, n = 76) during follow-up. The overall predictive capacity of the score was assessed using the area under the receiver operating characteristic (AUROC) curve. The effects of covariates on the receiver operating characteristic (ROC) curve were assessed using parametric ROC regression. The score cut-off validated for primary early infection (≥2.0) was used, from which the sensitivity and specificity were calculated. The AUROC was 0.74 (95% confidence interval (CI) = 0.63–0.84). Group sex significantly increased the predictive capacity. Using the validated cut-off, sensitivity was 70.4% (95%CI = 49.8–86.2%) and specificity was 59.2% (95%CI: 47.3–70.4%). External validation from a cohort of 25 cases and 111 controls, all MSM with HIV, resulted in a sensitivity of 44.0% (95%CI = 24.4–65.1) and specificity of 71.2% (95%CI = 61.8–79.4). The HCV-MOSAIC risk score may be useful for identifying individuals at risk of HCV reinfection. In sexual health or HIV-care settings, this score could help guide HCV-RNA testing in MSM with a prior HCV infection.

23 June 2025 in PLOS ONE
Verified
Journal Article
Open access
KHKris Hage
Kris Hage
KHKalongo Hamusonde
Kalongo Hamusonde
DSDaniela K. van Santen
Daniela K. van Santen
ANAstrid M. Newsum
Astrid M. Newsum
MVMarc van der Valk
Marc van der Valk
MPMaria Prins
Maria Prins
Certain key populations have a high risk of hepatitis C virus (HCV) reinfection, which includes men who have sex with men (MSM) with HIV who continue to engage in behaviors associated with HCV acquisition following clearance. Among MSM with HIV, we aimed to identify longitudinal sexual behavior patterns and estimate reinfection risk within identified patterns. MSM with HIV from the longitudinal, prospective Dutch MOSAIC study (2009–2018) at risk for HCV reinfection were included. Follow-up started following HCV clearance. Risk behavior was assessed using the HCV-MOSAIC score (range = 0.0–7.0), where ≥2 indicates high risk of reinfection. Classes were inferred from the mean HCV-MOSAIC score over time using a latent process mixed-effects model with the covariates age, group sex and casual partnership. The association between classes and HCV reinfection risk was assessed using a joint survival model. In total, 123 MSM were included with a median follow-up of 2.7 years [interquartile range (IQR) = 1.2–4.7]. Two classes were identified: one with mostly lower (C1, n = 67) and one with mostly higher risk behavior (C2, n = 56). During follow-up, both classes had considerable variation in HCV-MOSAIC scores (C1, median = 1.1, IQR = 0.0–2.1 and C2, median = 3.0, IQR = 2.0–3.5). HCV reinfection probability was similar between both classes at year 3 of follow-up [C1, 17%, 95% confidence interval (CI) = 11%−35% and C2, 18%, 95%CI = 15%−47%], but became higher in C2 than C1 at year 5 (C1, 22%, 95%CI = 13%−39% and C2, 37%, 95%CI = 28%−69%). The variation in risk over time suggests that behavioral assessment is continually needed for early testing, treatment and offering behavioral inventions.

15 March 2023 in Trials
Verified
Journal Article
Open access
PDF file
KHKris Hage
Kris Hage
ABAnders Boyd
Anders Boyd
UDUdi Davidovich
Udi Davidovich
PZPaul Zantkuijl
Paul Zantkuijl
EHElske Hoornenborg
Elske Hoornenborg
EWEjay de Wit
Ejay de Wit
Background: As highly effective therapy against hepatitis C virus (HCV) infection is available with rapid uptake, there is newfound optimism for HCV elimination. Nevertheless, certain key populations have a high risk of HCV reinfection, in particular men who have sex with men (MSM) in Western European countries. Modelling data indicate that HCV elimination will not be feasible without reduction in risk behaviour, thus supporting the need for effective interventions aimed at reducing risk behaviour and preventing reinfections in MSM. Methods: The ICECREAM study is an international, multi-centred, phase 2, 3-arm randomised trial comparing run-in and intervention periods enrolling MSM with a history of a cured or spontaneously cleared HCV infection. Individuals are followed in routine care for 6 months (i.e. run-in period) and then randomly allocated (1:1:1) to one of the following: a tailored, interactive online risk-reduction behavioural intervention, a validated home-based HCV-RNA self-sampling test service using dried blood spots, or a combination of both. After randomisation, individuals are followed every 6 months until 18 months (i.e. intervention period). Interventions are delivered in addition to standard of care. Online questionnaire measuring risk behaviour over the past 6 months is administered at every visit. The primary outcome is the proportion at risk of HCV infection during run-in versus intervention periods assessed by using the HCV-MOSAIC risk score. The risk score consists of six self-reported HCV-related risk behaviours. Secondary outcomes include incidence of HCV reinfection, changes in the individual risk behaviour items and changes in sexual well-being since changes in sexual behaviour may have an impact on sexual experience. Two hundred forty-six MSM aged 18 years or older will be invited to participate. Discussion: The ICECREAM study is a trial aimed at establishing interventions that could effectively decrease the incidence of HCV re-infection in MSM with a previous HCV infection. By offering an online behavioural risk-reduction intervention and HCV-RNA self-sampling, both of which are aimed to influence risk behaviour, we are able to provide products to at-risk MSM that could further reduce population-level HCV incidence and ultimately help reach HCV micro-elimination. Trial registration: ClinicalTrials.gov NCT04156945. Registered on November 8, 2019

1 January 2025 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
KHKris Hage
Kris Hage
ABAnders Boyd
Anders Boyd
DSDaniela K. van Santen
Daniela K. van Santen
KBKees Brinkman
Kees Brinkman
JAJoop Arends
Joop Arends
MPMaria Prins
Maria Prins
Background: Little is known about the effect of hepatitis C virus (HCV) treatment on sexual risk behavior among men who have sex with men (MSM) with HIV by treatment type (interferon [IFN]-based vs direct-acting antiviral [DAA]-based). Setting: MSM with HIV and recently acquired HCV infection enrolled in the MSM Observational Study of Acute Infection with hepatitis C (MOSAIC) cohort. Methods: Using data from 2009 to 2018, we evaluated risk behavior through a validated HCV risk score (where ≥2 indicated high risk) and its individual risk behaviors. Levels of risk behavior before, during, and after treatment were modeled for each treatment episode using linear and logistic regression with Generalized Estimating Equations adjusting for DAA availability and number of reinfections. Results: One hundred forty MSM with a median age of 45 years (interquartile range = 40–49) yielded 180 treatment episodes (n = 131 IFN-based, n = 49 DAA-based). Adjusted mean risk score before, during, and after treatment was 2.4 (95% confidence interval [CI] = 2.1 to 2.6), 0.9 (95% CI = 0.8 to 1.0), and 1.7 (95% CI = 1.5 to 1.8), respectively. Before treatment, no differences in mean HCV risk score or proportion of specific behaviors were found between the regimen groups. During treatment, MSM treated with DAAs had a higher average risk score and proportion of receptive condomless anal sex, sharing toys and unprotected fisting than those treated with IFN. After treatment, the proportion sharing straws were significantly higher in MSM treated with DAAs than in MSM treated with IFN. Conclusions: MSM treated with DAAs, compared with MSM treated with IFN, had higher levels of HCV-related risk behavior during treatment. The higher risk of HCV reinfection in the DAA-era underscores the need for ongoing HCV testing and behavioral interventions against HCV.